Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
NEO Transcript
NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript
Unknown10-28
The earnings call summary presents a mixed picture. While there are positive elements such as NGS growth and new product launches like PanTracer, there are also challenges like revised revenue guidance due to pharma uncertainties and potential negative EBITDA impact from Pathline integration. The Q&A session highlighted management's optimism but also revealed some vagueness in responses, particularly around timelines and competitive positioning. Given the company's small-cap status, the stock is likely to remain stable, leading to a neutral prediction.
NeoGenomics, Inc. (NEO) Q2 2025 Earnings Call Transcript
Unknown7-29
The earnings call summary shows mixed signals. While the company has a strong product development and partnership strategy, financial performance is affected by delays and market challenges. The Q&A reveals management's confidence in guidance despite uncertainties, but also highlights risks such as litigation and limited visibility in pharma services. The positive aspects such as the Pathline acquisition and NGS growth are balanced by cautious guidance and challenges in the pharma market. Given the company's market cap, the stock price is likely to remain stable in the short term, leading to a neutral prediction.
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2025 Earnings Call Transcript
Unknown4-30
The earnings call summary presents a mixed picture. Financial performance shows revenue growth, but EPS missed expectations. Product development is promising with new launches and NGS growth. Market strategy is strong, but operational challenges exist. Expenses are a concern with negative cash flow, though margins improved. No share repurchase plan is a negative. Q&A insights suggest optimism but also highlight non-clinical revenue declines and cautious guidance. Given the company's small-cap status, these factors balance out to a neutral sentiment, expecting minor stock price fluctuations in the short term.
NEO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
